Cosmetic cross-reference

Proline

CAS 147-85-3

Proline (CAS 147-85-3) is a Phase 2 pharmaceutical compound with 2 bioactivity targets and 5 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
7
SOURCE DrugCentral
Adverse signals
5
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Proline
CAS Number
147-85-3
UNII
9DLQ4CIU6V
InChIKey
ONIBWKKTOPOVIA-BYPYZUCNSA-N
ChEMBL ID
CHEMBL54922
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
L-proline
natural product
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2
Mid-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL54922 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 7 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- GI50 99265.71810344828 nM 58 -
- AC50 30000 nM 31 -
- Potency 22648.239999999998 nM 5 -
- IC50 19050.873333333333 nM 2 -
- Ki 86000 nM 1 -
Angiotensin-converting enzyme
Enzyme
Ki 4.07 - Homo sapiens
Glutamate receptor ionotropic, NMDA 1
Ion channel
IC50 4.76 - Rattus norvegicus
SOURCE DrugCentral 5 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Foetal growth restriction 15 64.616 10070531
Compartment syndrome 10 49.24 10010121
Device related sepsis 10 46.307 10069802
Vasoplegia syndrome 9 46.3 10067080
Infantile apnoea 8 44.253 10077321

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
Proline 8737 SU MTHSPL
PROLINE 8737 SU MTHSPL
proline 8737 SU MTHSPL
proline 8737 IN RXNORM
L-proline 8737 SY RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Proline used for in pharmaceutical contexts?

Proline (CAS 147-85-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Proline?

Proline has 5 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Foetal growth restriction, Compartment syndrome, Device related sepsis, Vasoplegia syndrome, Infantile apnoea. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Proline also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for L-Proline with EU status "permitted".

What clinical phase is Proline in?

Proline is rendered with ChEMBL max phase 2.

What bioactivity targets are documented for Proline?

Proline has 7 bioactivity rows in this page query. Rendered target entries include Angiotensin-converting enzyme, Glutamate receptor ionotropic, NMDA 1.